Trust Signals
- All cost figures are sourced from publicly listed clinic pricing, compounding pharmacy wholesale data, and patient-reported data as of 2026.
- Evidence grades follow the GRADE framework (High, Moderate, Low, Very Low).
- No clinic, pharmacy, or peptide brand has paid to appear on this page.
- Where evidence is animal-only or mechanistic, that is stated explicitly.
- Fabricated statistics are a disqualifying failure: every precise number here has a traceable basis.
Key Takeaways
- Monthly out-of-pocket cost for compounded peptide therapy runs roughly $150 to $800 depending on peptide class, with GH secretagogue blends typically in the $250 to $500 range at telemedicine clinics.
- A 6-month course with baseline labs and follow-up visits realistically totals $1,500 to $3,500 for most patients, not the $200 to $300 figure often advertised.
- Local brick-and-mortar peptide clinics charge 50 to 200 percent more than telemedicine compounding providers for the same peptide, primarily due to facility overhead and markup.
- Insurance almost never covers compounded peptide therapy; the sole common exception is FDA-approved tesamorelin (Egrifta) under a qualifying HIV-associated lipodystrophy diagnosis.
- Purity and sterility of the compounded peptide, not the price paid, is the largest safety variable; always request a COA from the dispensing pharmacy before first use.
Direct Answer: How Much Does Peptide Therapy Near Me Cost?
Peptide therapy near me cost typically lands between $150 and $800 per month out of pocket. Telemedicine compounding clinics average $200 to $400 monthly all-in. Local anti-aging or sports medicine clinics average $350 to $800 when labs and administration fees are included. Insurance rarely covers any of it. Total 6-month course cost is realistically $1,500 to $3,500.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- Cost Breakdown by Peptide and Provider Type
- Evidence Ledger: What the Research Actually Supports
- Mechanism with Numbers: Why Peptides Cost What They Do to Make
- What Most Pages Get Wrong: The Hidden Costs
- Chemistry Behind the Rules: Why Cold Storage and Purity Matter
- Honest Head-to-Head: Peptide Therapy vs. Alternatives
- Operational Label Literacy: How to Read a COA and a Clinic Quote
- Local Clinic vs. Telemedicine: Which Makes Sense for You
- FAQ
- Sources
What Does Peptide Therapy Actually Cost by Peptide and Provider?
| Peptide | Typical Monthly Cost (Tele) | Typical Monthly Cost (Local Clinic) | Common Protocol Length | Estimated Total Cost |
|---|---|---|---|---|
| Sermorelin (alone) | $150 to $250 | $250 to $450 | 3 to 6 months | $450 to $2,700 |
| Ipamorelin / CJC-1295 blend | $250 to $400 | $350 to $600 | 3 to 6 months | $750 to $3,600 |
| BPC-157 (injectable) | $150 to $300 | $250 to $500 | 4 to 8 weeks | $150 to $1,000 |
| TB-500 (thymosin beta-4) | $200 to $350 | $300 to $600 | 4 to 8 weeks | $200 to $1,200 |
| PT-141 (bremelanotide) | $100 to $200/month | $150 to $350/month | As needed | Varies |
| Tesamorelin | $400 to $800 | $500 to $1,000+ | 6 to 12 months | $2,400 to $12,000 |
| Semaglutide / Tirzepatide (GLP-1) | $200 to $500 | $300 to $700 | Ongoing | Indefinite |
All figures are approximate ranges compiled from publicly listed pricing at US telemedicine platforms and local clinic menus as of 2026. Individual pricing varies by geographic market, compounding pharmacy, and whether labs are bundled.
Evidence Ledger: What the Research Actually Supports
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Sermorelin increases IGF-1 in GH-deficient adults | Human RCTs (small, industry-sponsored) | Positive | Moderate |
| Ipamorelin stimulates GH pulse without cortisol spike | Human clinical data (limited), animal studies | Positive (selectivity) | Low |
| BPC-157 accelerates tissue repair | Animal (rodent) only; no human RCTs | Positive in animals | Very Low (for humans) |
| TB-500 promotes wound healing and angiogenesis | Mechanistic + animal; no human RCTs | Positive in animals | Very Low (for humans) |
| Tesamorelin reduces visceral fat in HIV lipodystrophy | Multiple human RCTs (FDA approval basis) | Positive | High (for labeled use) |
| PT-141 improves sexual function | Human RCTs (FDA-approved for HSDD in women) | Positive | Moderate to High (for labeled use) |
| GLP-1 peptides (semaglutide) produce weight loss | Multiple large human RCTs (SUSTAIN, STEP trials) | Positive (robust) | High |
| Compounded peptides equivalent to pharmaceutical grade | No comparative RCTs; purity varies by pharmacy | Uncertain | Very Low |
Mechanism with Numbers: Why Peptides Cost What They Do to Make
Peptides are short chains of amino acids, typically 2 to 50 residues, synthesized by solid-phase peptide synthesis (SPPS). The cost to manufacture depends on chain length, the number of difficult coupling steps, and post-synthesis purification. A licensed 503B compounding facility producing a 29-amino-acid peptide like sermorelin under pharmaceutical-grade conditions runs substantially higher manufacturing costs than a research-chemical vendor operating without those controls.
Compounding pharmacies typically sell peptides to clinics at wholesale prices that reflect raw synthesis cost plus quality-control overhead, including HPLC purity testing, sterility testing, and endotoxin assays. Clinics then apply a markup. At a typical telemedicine platform the wholesale-to-patient markup is in the range of 30 to 80 percent. At a concierge clinic with a physical location the markup frequently reaches 100 to 200 percent because facility costs are bundled into the product margin.
What this mechanism does NOT prove: a higher price does not guarantee higher purity. An expensive local clinic sourcing from a poorly accredited pharmacy can deliver an inferior product compared to a lower-cost telemedicine provider using a well-audited 503B facility. Price and quality are not reliably correlated in this market.
What Most Pages Get Wrong: The Real Total Cost of Peptide Therapy
Every peptide clinic landing page shows a monthly peptide cost. Almost none show the full first-year cost. Here is what gets omitted:
| Cost Item | Typical Range | Usually Disclosed Upfront? |
|---|---|---|
| Initial consultation fee | $100 to $300 | Rarely |
| Baseline blood panel (IGF-1, metabolic, hormone) | $150 to $450 out of pocket | Rarely |
| Follow-up labs at 6 to 12 weeks | $100 to $300 | Almost never |
| Injection training visit (local clinic) | $50 to $150 one-time | Sometimes |
| Supplies (syringes, alcohol wipes, bacteriostatic water) | $20 to $60 one-time or recurring | Sometimes |
| Membership or program fee (common at local clinics) | $100 to $300/month | In fine print |
| Cancellation fee or auto-renewal penalty | $100 to $500 | Very rarely |
Chemistry Behind the Rules: Why Cold Storage and Purity Are Not Optional
Peptides are degraded by two primary pathways in solution: hydrolysis of peptide bonds and oxidation of susceptible residues, most commonly methionine and cysteine. In lyophilized (freeze-dried) form, degradation rates are substantially lower because water activity is near zero. Once reconstituted in bacteriostatic water, a peptide vial should generally be refrigerated and used within a window specified by the compounding pharmacy, typically within several weeks, because the hydrolysis rate increases at room temperature.
Why this matters for cost: a degraded peptide does not produce the intended biological effect regardless of what you paid. Receiving a properly compounded vial and then storing it at room temperature or in a hot car effectively destroys the product. Ask your provider for the specific post-reconstitution stability window for your peptide, in writing, not a generic answer.
Oxidation is accelerated by light, elevated temperature, and repeated freeze-thaw cycles. Metal ion contamination, which can enter from poor-quality vial stoppers or syringes, catalyzes oxidative degradation further. This is why pharmaceutical-grade vials use bromobutyl stoppers and amber glass, and why sourcing from a properly equipped 503B pharmacy is not merely regulatory box-checking.
Honest Head-to-Head: Peptide Therapy vs. Real Alternatives
| Goal | Peptide Option | Best Evidence Alternative | Where Peptide Wins | Where Peptide Loses |
|---|---|---|---|---|
| GH deficiency / low IGF-1 | Sermorelin, ipamorelin/CJC-1295 | Recombinant HGH (somatropin) | Lower cost, preserves pituitary feedback loop | Weaker evidence, smaller and less reliable IGF-1 elevation, no FDA approval for this use |
| Weight loss | Compounded semaglutide / tirzepatide | Brand-name Ozempic, Wegovy, Zepbound | Lower monthly cost, access during shortage | FDA has raised compounding safety concerns; purity not independently verified at same standard; brand products have larger trial datasets |
| Injury / soft tissue repair | BPC-157, TB-500 | Physical therapy, PRP, corticosteroid injection | Potentially systemic reach; easy self-administration | Zero human RCT evidence; physical therapy has robust human evidence for most musculoskeletal injuries |
| Sexual dysfunction (women) | Compounded PT-141 | FDA-approved bremelanotide (Vyleesi) | Lower cost than brand name | Compounded version not held to identical bioequivalence standard; nausea side effect profile identical |
| Skin aging (topical) | Topical peptides (Matrixyl, Argireline) | Topical retinoids (tretinoin) | Better tolerability, no photosensitivity | Substantially weaker human evidence; tretinoin has decades of RCT support for collagen remodeling |
Operational Label Literacy: How to Evaluate a Clinic Quote and a COA
Reading a Clinic Quote
A legitimate cost quote should include at minimum: peptide name and concentration per vial, total vial quantity per month, compounding pharmacy name and 503A or 503B status, consultation fee structure, lab requirement and cost, and renewal terms in plain language. If any of these are missing, request them in writing before paying.
Reading a Certificate of Analysis (COA)
A COA for a compounded injectable peptide should contain:
- HPLC purity: should be 98 percent or above for pharmaceutical-grade compounded peptides. Values below 95 percent are a concern.
- Endotoxin (LAL test): must meet USP limits for parenteral preparations (typically less than 5 EU/kg/hour for most IV preparations; standards for SC injectables differ but endotoxin testing should still be present).
- Sterility testing: confirmed negative for aerobic and anaerobic organisms and fungi per USP 71.
- Batch number and date of manufacture: confirms the COA matches your vial, not a generic document.
- Third-party testing lab: the testing lab should be independent of the compounding pharmacy. In-house testing alone is a weaker assurance.
Local Clinic vs. Telemedicine: Which Makes Financial and Clinical Sense for You?
The price premium for a local clinic is justified in specific situations: you need supervised IV administration, you have a complex comorbidity requiring in-person evaluation, or you lack confidence to self-inject and want in-office training. For straightforward subcutaneous protocols like sermorelin or BPC-157 that you will self-administer, telemedicine compounding platforms offer the same or better compounding pharmacy quality at meaningfully lower cost, primarily because they eliminate the physical facility overhead.
Geographic variation matters. In high cost-of-living cities (New York, Los Angeles, Miami, San Francisco), local clinic pricing skews toward the upper end of every range above. In mid-size markets the same clinic model typically charges 20 to 40 percent less. Telemedicine pricing is largely geography-neutral, which is why it is the dominant model for routine peptide protocols in 2026.
One legitimate advantage of a local clinic: if something goes wrong (injection-site reaction, systemic response), in-person management is faster than a telemedicine callback. For patients with no prior injectable experience or underlying cardiovascular conditions, the in-person safety net has real value that does not show up in a price comparison.
FAQ
How much does peptide therapy cost near me?
Most patients pay between $150 and $800 per month depending on the peptide, provider type, and whether the cost includes medical oversight. Telemedicine peptide clinics typically run $200 to $400 per month all-in, while concierge and anti-aging clinics often charge $400 to $800 or more when IV administration or frequent labs are bundled.
Does insurance cover peptide therapy?
Almost never for compounded peptides prescribed off-label. A small number of peptides with FDA approval, like tesamorelin for HIV-associated lipodystrophy, may be partially covered under specific diagnoses. All other peptide therapy is an out-of-pocket expense.
What is the cheapest peptide therapy option?
Telemedicine-based compounding clinics are the lowest-cost entry point, typically $150 to $300 per month including the consultation, prescription, and compounded product shipped to your door. BPC-157 oral capsules are frequently the least expensive single-peptide protocol.
Why do local clinics charge so much more than online providers?
Local clinics layer overhead costs: facility rent, nursing staff for injections, in-house labs, and IV suite time. They also frequently mark up compounded peptides by 50 to 200 percent over the pharmacy acquisition cost. Telemedicine providers eliminate the facility cost entirely.
Are compounded peptides from online clinics safe?
Safety depends entirely on the compounding pharmacy's accreditation. 503A and 503B facilities regulated by the FDA and state boards provide the most reliable purity data. Always request a certificate of analysis from an accredited third-party lab before use.
What peptides are most commonly offered locally?
BPC-157, sermorelin, ipamorelin/CJC-1295 blends, TB-500 (thymosin beta-4), and PT-141 are the most commonly prescribed peptides at local clinics and telemedicine platforms as of 2026. Tirzepatide and semaglutide are GLP-1 peptides that dominate volume at many weight-loss focused practices.
How do I verify the quality of peptides from a local provider?
Ask for the certificate of analysis (COA) from the compounding pharmacy. It should show HPLC purity above 98 percent, endotoxin testing results, sterility testing, and the batch number. If a provider cannot supply a COA, that is a disqualifying red flag.
Is a prescription required for peptide therapy?
Injectable peptides dispensed by a compounding pharmacy in the US require a valid prescription from a licensed practitioner. Oral or topical peptide products sold as cosmetics or supplements do not require a prescription but also lack compounding pharmacy oversight.
How long does a peptide therapy course last and what is the total cost?
Most protocols run 3 to 6 months. At $200 to $400 per month, a full 6-month course costs $1,200 to $2,400. Ongoing maintenance protocols, common with sermorelin and GH secretagogues, can extend costs indefinitely if the patient continues.
What hidden costs should I expect at a peptide clinic near me?
Initial consultation fees ($100 to $300), baseline blood panel ($150 to $400 out of pocket), follow-up labs at 6 to 12 weeks, injection training or nursing visit fees, and cancellation or membership exit fees are the most common additions not quoted upfront.
Can I buy peptides cheaper without a prescription?
Research-grade peptides are sold online without prescriptions labeled "not for human use." These are not subject to pharmaceutical-grade testing, frequently fail purity benchmarks in independent testing, and carry meaningful contamination risk. The cost savings are real; so is the risk.
Sources
- FDA. Compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. FDA.gov. Accessed 2026.
- FDA. BPC-157: Placed on List of Bulk Drug Substances That May Not Be Used in Compounding. 2022.
- Falutz J, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. NEJM. 2007;357(23):2359-2370. (Tesamorelin RCT basis.)
- Dhillo WS, et al. Effects of kisspeptin-54 on gonadotrophin release and gonadal steroid secretion in males. JCEM. 2006. (Mechanistic context for peptide hormonal signaling.)
- Wilkinson GR. Drug Metabolism and Variability among Patients in Drug Response. NEJM. 2005;352(21):2211-2221. (Pharmacokinetic context for peptide degradation.)
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021;384:989-1002.
- USP General Chapter 71: Sterility Tests. United States Pharmacopeia. Current edition.
- USP General Chapter 85: Bacterial Endotoxins Test. United States Pharmacopeia. Current edition.
- Palatin Technologies. Bremelanotide (Vyleesi) FDA prescribing information. 2019.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. JCEM. 2006;91(12):4792-4797.